{"id":"NCT04505722","sponsor":"Janssen Vaccines & Prevention B.V.","briefTitle":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants","officialTitle":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-07","primaryCompletion":"2023-03-31","completion":"2023-03-31","firstPosted":"2020-08-10","resultsPosted":"2022-04-15","lastUpdate":"2025-02-04"},"enrollment":44325,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol"],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.COV2.S","otherNames":["JNJ-78436735","Ad26COVS1"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ad26.COV2.S","type":"EXPERIMENTAL"},{"label":"Placebo","type":"EXPERIMENTAL"}],"summary":"The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.","primaryOutcome":{"measure":"Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease (COVID-19) With Seronegative Status With Onset at Least 14 Days After Double-blind Vaccination on Day 1 (Day 15): Double-blind Phase","timeFrame":"From 14 days after double-blind vaccination on Day 1 (Day 15) up to Month 6","effectByArm":[{"arm":"Double-blind Phase: Ad26.COV2.S 5*10^10 vp","deltaMin":381,"sd":null},{"arm":"Double-blind Phase: Placebo","deltaMin":847,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":225,"countries":["United States","Argentina","Brazil","Chile","Colombia","Mexico","Peru","South Africa"]},"refs":{"pmids":["39532861","39225478","37385888","36357712","35139271","34824596","33882225","33524316"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":235,"n":21898},"commonTop":["Vaccination site pain(Solicited)","Fatigue(Solicited)","Headache (Solicited)","Myalgia(Solicited)","Nausea(Solicited)"]}}